{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:19:29Z","timestamp":1791335969179,"version":"4.3.1"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The gut microbiome, a metabolically active community of microorganisms in the gastrointestinal tract, regulates host immunity, metabolism, and inflammation. Dysbiosis, or disruption of this ecosystem, has been linked to cancer initiation, progression, and therapy resistance. Triple-negative breast cancer (TNBC) accounts for 10\u201315% of breast cancers and is managed primarily with chemotherapy and immune checkpoint inhibitors; however, treatment responses remain variable and these patients are at higher risk of cancer recurrence compared to patients with hormone receptor-positive or HER2-positive breast cancer. Emerging evidence suggests that the gut microbial composition and its diversity can influence outcomes and therapeutic efficacy of systemic treatments in TNBC. We review the current epidemiologic, mechanistic, and clinical evidence on how the gut microbiome influences TNBC biology, with particular attention to the tumor immune microenvironment and response to therapy. We highlight protective and pro-tumorigenic microbial signatures, the impact of antibiotics and obesity, and emerging strategies, such as dietary modulation and microbiome-targeted interventions, that may ultimately be used to optimize TNBC management and improve patient outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2026.1832176","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:01:35Z","timestamp":1779426095000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond the tumor: the role of the gut microbiome in triple-negative breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Armina","family":"Saadatkhah","sequence":"first","affiliation":[{"name":"University of California, San Diego","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Nicholson","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Scripps Research","place":["La Jolla, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Buchholz","sequence":"additional","affiliation":[{"name":"Scripps Cancer Center, Scripps Health","place":["San Diego, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Hong","sequence":"additional","affiliation":[{"name":"Clinical Assistant Professor, Department of Medical Oncology and Therapeutics Research, City of Hope Lennar Foundation Cancer Center","place":["Irvine, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S516125","article-title":"Triple-negative breast cancer on the rise: Breakthroughs and beyond","volume":"17","author":"Agelidis","year":"2025","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4274\/ejbh.galenos.2025.2024-10-2","article-title":"Prognostic significance and molecular classification of triple negative breast cancer: A systematic review","volume":"21","author":"Dogra","year":"2025","journal-title":"Eur J Breast Health"},{"key":"B3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tbcr-24-28","article-title":"Targeting low-risk triple-negative breast cancer: A review on de-escalation strategies for a new era","volume":"6","author":"Carvalho","year":"2025","journal-title":"Transl Breast Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae064","article-title":"Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: A real-world analysis","volume":"29","author":"LeVee","year":"2024","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1186\/s12885-023-11293-4","article-title":"Neoadjuvant immunotherapy and chemotherapy regimens for the treatment of high-risk, early-stage triple-negative breast cancer: A systematic review and network meta-analysis","volume":"23","author":"Cortes","year":"2023","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1020121","article-title":"Understanding and harnessing triple-negative breast cancer-related microbiota in oncology","volume":"12","author":"Devoy","year":"2022","journal-title":"Front Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2022.07.014","article-title":"Gut microbiome and breast-feeding: Implications for early immune development","volume":"150","author":"Davis","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.2191","article-title":"The microbiome and cancer: A translational science review","volume":"333","author":"Fernandez","year":"2025","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/metabo14120683","article-title":"Emerging role of gut microbiota in breast cancer development and its implications in treatment","volume":"14","author":"Mir","year":"2024","journal-title":"Metabolites"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092465","article-title":"Breast and gut microbiota action mechanisms in breast cancer pathogenesis and treatment","volume":"12","author":"Laborda-Illanes","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2021.10.068","article-title":"Gut microbiota and immunity relevance in eubiosis and dysbiosis","volume":"29","author":"Al-Rashidi","year":"2022","journal-title":"Saudi J Biol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad060","article-title":"Characterization of gut microbiome composition in patients with triple-negative breast cancer treated with neoadjuvant chemotherapy","volume":"28","author":"Vernaci","year":"2023","journal-title":"Oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2221452","article-title":"The gut microbiota in breast cancer development and treatment: The good, the bad, and the useful","volume":"15","author":"Nandi","year":"2023","journal-title":"Gut Microbes"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmic.2025.100155","article-title":"The gut microbiota and breast cancer: A comprehensive review of emerging links and therapeutic implications","volume":"26","author":"Nazeer","year":"2025","journal-title":"Med Microecol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1038\/s41467-023-37636-0","article-title":"Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer","volume":"14","author":"Ransohoff","year":"2023","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13760","article-title":"Gut microbiota diversity is prognostic and associated with benefit from chemo\u2010immunotherapy in metastatic triple\u2010negative breast cancer","volume":"19","author":"Ullern","year":"2025","journal-title":"Mol Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107726","article-title":"Gut microbiota reshapes the TNBC immune microenvironment: Emerging immunotherapeutic strategies","volume":"215","author":"Huang","year":"2025","journal-title":"Pharmacol Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115516","article-title":"Intra-tumoral bacteria in breast cancer and intervention strategies","volume":"217","author":"Hou","year":"2025","journal-title":"Adv Drug Delivery Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41392-023-01693-0","article-title":"Intratumoral microbiota: A new frontier in cancer development and therapy","volume":"9","author":"Cao","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41522-025-00816-5","article-title":"Unravelling novel microbial players in the breast tissue of TNBC patients: A meta-analytic perspective","volume":"11","author":"Rashwan","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.aninu.2021.11.005","article-title":"Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation","volume":"8","author":"Akhtar","year":"2022","journal-title":"Anim Nutr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25473","article-title":"Body microbiota and its relationship with benign and Malignant breast tumors: A systematic review","volume":"14","author":"Samkari","year":"2022","journal-title":"Cureus"},{"key":"B23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/PPO.0000000000000502","article-title":"Obesity and energy balance considerations in triple-negative breast cancer","volume":"27","author":"Berger","year":"2021","journal-title":"Cancer J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41523-021-00325-6","article-title":"Overweight and prognosis in triple-negative breast cancer patients: A systematic review and meta-analysis","volume":"7","author":"Harborg","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123082","article-title":"Unveiling the intricate dance: Obesity and TNBC connection examined","volume":"357","author":"Newport-Ratiu","year":"2024","journal-title":"Life Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/nu13103656","article-title":"Obesity modulates the gut microbiome in triple-negative breast cancer","volume":"13","author":"Hossain","year":"2021","journal-title":"Nutrients"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-025-02322-y","article-title":"Mutational landscape of triple-negative breast cancer in African American women","volume":"57","author":"Yao","year":"2025","journal-title":"Nat Genet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.576964","article-title":"Racial disparities in triple negative breast cancer: A review of the role of biologic and non-biologic factors","volume":"8","author":"Prakash","year":"2020","journal-title":"Front Public Health"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3896","article-title":"Triple-negative breast cancer in African-American women: Disparities versus biology","volume":"15","author":"Dietze","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0138","article-title":"African ancestry-associated gene expression profiles in triple-negative breast cancer underlie altered tumor biology and clinical outcome in women of African descent","volume":"12","author":"Martini","year":"2022","journal-title":"Cancer Discov"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.49798","article-title":"West African genetic ancestry and breast cancer outcomes among black women","volume":"7","author":"Reid","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169490","article-title":"Gut metabolites and breast cancer: The continuum of dysbiosis, breast cancer risk, and potential breast cancer therapy","volume":"23","author":"Jaye","year":"2022","journal-title":"IJMS"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193248","article-title":"Guardians in the gut: Mechanistic insights into a hidden ally against triple-negative breast cancer","volume":"17","author":"Jaye","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2025.112162","article-title":"Enriched pathways in gut microbiome predict response to immune checkpoint inhibitor treatment across demographic regions and various cancer types","volume":"28","author":"Cai","year":"2025","journal-title":"iScience"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2017.1429","article-title":"Triple-negative breast cancer and its association with obesity","volume":"7","author":"Sun","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","article-title":"Gut microbiota influence immunotherapy responses: Mechanisms and therapeutic strategies","volume":"15","author":"Lu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12967-020-02424-7","article-title":"ALICE: A randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer","volume":"18","author":"Kyte","year":"2020","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115572","article-title":"Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacy","volume":"225","author":"Vion","year":"2025","journal-title":"Eur J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010365","article-title":"Intratumoral microbiota predicts the response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.cmet.2022.02.010","article-title":"The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer","volume":"34","author":"Wang","year":"2022","journal-title":"Cell Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01360","article-title":"Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: Inflammation mechanism, clinical prognostic, and potential as a therapeutic target","volume":"10","author":"Yang","year":"2019","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/metabo15060364","article-title":"Plasma TMAO concentrations and gut microbiota composition in subjects with and without metabolic syndrome: Results from pilot study","volume":"15","author":"Hefni","year":"2025","journal-title":"Metabolites"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101733","article-title":"The specific hallmarks, emerging roles, key mechanisms, and clinical applications of intra-tumoral microbiota in human cancers","volume":"13","author":"Zhao","year":"2026","journal-title":"Genes Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"P3-12-34","DOI":"10.1158\/1538-7445.SABCS21-P3-12-34","article-title":"Abstract P3-12-34: Antibiotic use and mortality from triple-negative breast cancer","volume":"82","author":"Ransohoff","year":"2022","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4666380","article-title":"Endotoxin triggers tumor initiation events in nontumorigenic breast epithelial cells and enhances invasion-related phenotype in pretumorigenic and tumorigenic breast epithelial cells","volume":"2021","author":"Yassine","year":"2021","journal-title":"Int J Inflam"},{"key":"B46","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41522-025-00786-8","article-title":"Gut microbiota shapes cancer immunotherapy responses","volume":"11","author":"Lei","year":"2025","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2560695","article-title":"The intratumoral microbiota in breast cancer: From basic research to clinical translation","volume":"17","author":"Xu","year":"2025","journal-title":"Gut Microbes"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/agm2.12359","article-title":"Intratumoral microbiota as cancer therapeutic target","volume":"7","author":"Guo","year":"2024","journal-title":"Aging Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12943-025-02403-w","article-title":"The tumor microbiome in cancer progression: Mechanisms and therapeutic potential","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188990","article-title":"Modulating the gut microbiota by probiotics, prebiotics, postbiotics, and fecal microbiota transplantation: an emerging trend in cancer patient care","volume":"1878","author":"Ciernikova","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32003","article-title":"Fecal microbiota transplantation in cancer management: current status and perspectives","volume":"145","author":"Chen","year":"2019","journal-title":"Int J Cancer"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100877","article-title":"Gut microbiota predictive of the efficacy of consolidation immunotherapy and chemoradiotherapy toxicity in lung cancer","volume":"6","author":"Wu","year":"2025","journal-title":"Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13111034","article-title":"Antibiotic-induced immunosuppression-a focus on cellular immunity","volume":"13","author":"Snow","year":"2024","journal-title":"Antibiot (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103644","article-title":"Gut Ruminococcaceae levels at baseline correlate with risk of antibiotic-associated diarrhea","volume":"25","author":"Gu","year":"2022","journal-title":"iScience"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126597","article-title":"The intestinal microbiota: impacts of antibiotics therapy, colonization resistance, and diseases","volume":"22","author":"Shah","year":"2021","journal-title":"IJMS"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T05:01:37Z","timestamp":1779426097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1832176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":57,"alternative-id":["10.3389\/fonc.2026.1832176"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1832176","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"article-number":"1832176"}}